You just read:

IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases

News provided by

IFM Therapeutics, LLC

Jul 19, 2018, 07:30 ET